Preferred Label : DLK1/EPHA2/HBB/NRP1/RGS5/TEM1 Peptide-pulsed Alpha-type-1 Polarized Dendritic Cell
Vaccine;
NCIt synonyms : alphaDC1-TBVA Vaccine; Tumor Blood Vessel Antigen Peptide-pulsed Alpha-type-1 Polarized Dendritic Cell Vaccine;
NCIt definition : A cell based cancer vaccine composed of mature polarized dendritic cells (alphaDC1)
pulsed with six human leukocyte antigen (HLA)-A2-presented tumor blood vessel antigen
(TBVA)-derived peptides, with potential immunostimulatory and antineoplastic activities.
Dendritic cells (DCs) were treated with a type-1 polarizing cytokine cocktail, including
interleukin-1beta, tumor necrosis factor alpha (TNF-a), interferon-alpha (IFN-a),
IFN-gamma and polyinosinic:polycytidylic acid (pI:C) to produce mature alpha type-1
polarized DCs (alphaDC1) that are capable of producing high levels of interleukin-12p70
(IL-12p70). The alphaDC1 are subsequently pulsed with TBVA-derived peptides, including
delta-like homologue 1 (DLK1) 310-318, EPH receptor A2 (EPHA2) 883-891, beta-globin
(HBB) 31-39, neuropilin-1 (NRP1) 433-441, regulator of G-protein signaling 5 (RGS5)
5-13 and tumor endothelial marker 1 (TEM1) 691-700. Upon administration, these DCs
are able to induce a potent cytotoxic T-lymphocyte (CTL) response against the TBVAs
expressed on tumor-associated stromal cells, which results in stromal cell lysis and
inhibition of angiogenesis. Disrupting the surrounding tumor vasculature inhibits
tumor cell growth and survival. alphaDC1 are able to induce a potent tumor antigen-specific
CTL response due to their high co-stimulatory activity and the secretion of anti-cancer
cytokines, such as IL-12p70.;
NCI Metathesaurus CUI : CL471790;
Origin ID : C113807;
UMLS CUI : C3830413;
Semantic type(s)
- concept_is_in_subset
- has_target
